Orthocell Limited (OCC.AX)
| Previous close | 0.5300 |
| Open | 0.5300 |
| Bid | 0.5350 x 3162600 |
| Ask | 0.5400 x 365000 |
| Day's range | 0.5250 - 0.5400 |
| 52-week range | 0.3200 - 0.6550 |
| Volume | 257,386 |
| Avg. volume | 422,352 |
| Market cap | 101.962M |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0460 |
| Earnings date | 27 Aug 2018 - 31 Aug 2018 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Epazz Provitrac Applicant Tracking System Video Interviewing Feature is Available for Companies Changing to the New Hybrid Work Environments After COVID-19 Pandemic
Provitrac video interviewing software assists companies with hiring employees who will be working from home or part-time in the office CHICAGO, IL, June 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Epazz Inc. (OTC: EPAZ), the parent company of DeskFlex, a mission-critical provider of cloud-based business software solutions, announced today that their Provitrac applicant tracking software solution announced the launching of the video interviewing feature that assists companies with the new Hy
- Simply Wall St.
Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- Business Wire
Orthocell Receives US Market Clearance
Australian-based regenerative medicine company, Orthocell Ltd (ASX:OCC, "Orthocell" or the "Company"), has achieved US 510k clearance to market and supply its collagen medical device Striate+TM in the US dental bone and tissue regeneration market.
